What is CranioSense?
CranioSense is at the forefront of medical technology, dedicated to enhancing the management of intracranial pressure (ICP) for patients suffering from traumatic brain injuries (TBIs). The company has engineered a groundbreaking non-invasive system named IPASS. This system utilizes a patch and sensors to rapidly and safely measure ICP, thereby circumventing the need for traditional invasive procedures. By offering a less risky and more efficient method, CranioSense aims to significantly improve patient outcomes in both intensive care units and pre-hospital emergency response scenarios. Their technology is designed to assist healthcare professionals and first responders in addressing the critical challenge of elevated cranial pressure.
How much funding has CranioSense raised?
CranioSense has raised a total of $5.5M across 1 funding round:
Grant
$5.5M
Grant (2025): $5.5M, investors not publicly disclosed
What's next for CranioSense?
The substantial enterprise-level funding and recent strategic investment signal a pivotal growth phase for CranioSense. This capital infusion is expected to accelerate the company's product development, expand its market reach, and potentially fund further clinical trials or regulatory approvals. The focus on non-invasive ICP monitoring addresses a critical unmet need in neurocritical care, positioning CranioSense for significant impact and market penetration. Future endeavors will likely involve scaling manufacturing, building out sales and distribution channels, and forging strategic partnerships within the healthcare ecosystem to ensure widespread adoption of their life-saving technology.
See full CranioSense company page
